vs
Fair Isaac（FICO）とUNITED THERAPEUTICS Corp（UTHR）の財務データ比較。上の社名をクリックして会社を切り替えられます
UNITED THERAPEUTICS Corpの直近四半期売上が大きい（$790.2M vs $512.0M、Fair Isaacの約1.5倍）。UNITED THERAPEUTICS Corpの純利益率が高く（46.1% vs 30.9%、差は15.2%）。Fair Isaacの前年同期比売上増加率が高い（16.4% vs 7.4%）。Fair Isaacの直近四半期フリーキャッシュフローが多い（$173.9M vs $173.3M）。過去8四半期でFair Isaacの売上複合成長率が高い（8.6% vs 8.0%）
FICO（旧社名Fair, Isaac and Company）は米国モンタナ州ボーズマンに本社を置くデータ分析企業で、1956年にビル・フェアとアール・アイザックにより創業されました。消費者の信用リスクを測定するFICOスコアは、米国の消費者融資業界で広く活用されています。
ユナイテッド・セラピューティクスは米国のバイオテクノロジー企業で、異種移植を含む臓器移植関連の医薬品や技術を開発しています。主力製品の多くは肺疾患治療や臓器製造分野向けで、メリーランド州とノースカロライナ州に2つの本社を置き、米国各地やカナダにも拠点を構えています。
FICO vs UTHR — 直接比較
損益計算書 — Q1 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $512.0M | $790.2M |
| 純利益 | $158.4M | $364.3M |
| 粗利率 | 83.0% | 86.9% |
| 営業利益率 | 45.7% | 45.1% |
| 純利益率 | 30.9% | 46.1% |
| 売上前年比 | 16.4% | 7.4% |
| 純利益前年比 | 3.8% | 20.9% |
| EPS（希薄化後） | $6.61 | $7.66 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $512.0M | $790.2M | ||
| Q3 25 | $515.8M | $799.5M | ||
| Q2 25 | $536.4M | $798.6M | ||
| Q1 25 | $498.7M | $794.4M | ||
| Q4 24 | $440.0M | $735.9M | ||
| Q3 24 | $453.8M | $748.9M | ||
| Q2 24 | $447.8M | $714.9M | ||
| Q1 24 | $433.8M | $677.7M |
| Q4 25 | $158.4M | $364.3M | ||
| Q3 25 | $155.0M | $338.7M | ||
| Q2 25 | $181.8M | $309.5M | ||
| Q1 25 | $162.6M | $322.2M | ||
| Q4 24 | $152.5M | $301.3M | ||
| Q3 24 | $135.7M | $309.1M | ||
| Q2 24 | $126.3M | $278.1M | ||
| Q1 24 | $129.8M | $306.6M |
| Q4 25 | 83.0% | 86.9% | ||
| Q3 25 | 82.3% | 87.4% | ||
| Q2 25 | 83.7% | 89.0% | ||
| Q1 25 | 82.4% | 88.4% | ||
| Q4 24 | 80.1% | 89.7% | ||
| Q3 24 | 80.3% | 88.9% | ||
| Q2 24 | 80.3% | 89.1% | ||
| Q1 24 | 80.0% | 89.2% |
| Q4 25 | 45.7% | 45.1% | ||
| Q3 25 | 46.0% | 48.6% | ||
| Q2 25 | 48.9% | 45.6% | ||
| Q1 25 | 49.3% | 48.2% | ||
| Q4 24 | 40.8% | 48.6% | ||
| Q3 24 | 43.4% | 45.8% | ||
| Q2 24 | 42.5% | 44.7% | ||
| Q1 24 | 44.9% | 52.6% |
| Q4 25 | 30.9% | 46.1% | ||
| Q3 25 | 30.1% | 42.4% | ||
| Q2 25 | 33.9% | 38.8% | ||
| Q1 25 | 32.6% | 40.6% | ||
| Q4 24 | 34.7% | 40.9% | ||
| Q3 24 | 29.9% | 41.3% | ||
| Q2 24 | 28.2% | 38.9% | ||
| Q1 24 | 29.9% | 45.2% |
| Q4 25 | $6.61 | $7.66 | ||
| Q3 25 | $6.41 | $7.16 | ||
| Q2 25 | $7.40 | $6.41 | ||
| Q1 25 | $6.59 | $6.63 | ||
| Q4 24 | $6.14 | $6.23 | ||
| Q3 24 | $5.44 | $6.39 | ||
| Q2 24 | $5.05 | $5.85 | ||
| Q1 24 | $5.16 | $6.17 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $162.0M | $2.9B |
| 総負債低いほど良い | $3.2B | — |
| 株主資本純資産 | $-1.8B | $7.1B |
| 総資産 | $1.9B | $7.9B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $162.0M | $2.9B | ||
| Q3 25 | $134.1M | $2.8B | ||
| Q2 25 | $189.0M | $3.0B | ||
| Q1 25 | $146.6M | $3.3B | ||
| Q4 24 | $184.3M | $3.3B | ||
| Q3 24 | $150.7M | $3.3B | ||
| Q2 24 | $156.0M | $3.0B | ||
| Q1 24 | $135.7M | $2.7B |
| Q4 25 | $3.2B | — | ||
| Q3 25 | $3.1B | — | ||
| Q2 25 | $2.8B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.1B | — | ||
| Q1 24 | $2.0B | — |
| Q4 25 | $-1.8B | $7.1B | ||
| Q3 25 | $-1.7B | $6.6B | ||
| Q2 25 | $-1.4B | $7.2B | ||
| Q1 25 | $-1.1B | $6.8B | ||
| Q4 24 | $-1.1B | $6.4B | ||
| Q3 24 | $-962.7M | $6.1B | ||
| Q2 24 | $-829.3M | $5.7B | ||
| Q1 24 | $-735.7M | $5.3B |
| Q4 25 | $1.9B | $7.9B | ||
| Q3 25 | $1.9B | $7.4B | ||
| Q2 25 | $1.9B | $7.9B | ||
| Q1 25 | $1.8B | $7.7B | ||
| Q4 24 | $1.7B | $7.4B | ||
| Q3 24 | $1.7B | $7.1B | ||
| Q2 24 | $1.7B | $6.7B | ||
| Q1 24 | $1.7B | $6.5B |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $174.1M | $346.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $173.9M | $173.3M |
| FCFマージンFCF / 売上 | 34.0% | 21.9% |
| 設備投資強度設備投資 / 売上 | 0.0% | 21.9% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 0.95× |
| 直近12ヶ月FCF直近4四半期 | $750.6M | $1.0B |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $174.1M | $346.2M | ||
| Q3 25 | $223.7M | $562.1M | ||
| Q2 25 | $286.2M | $191.7M | ||
| Q1 25 | $74.9M | $461.2M | ||
| Q4 24 | $194.0M | $341.2M | ||
| Q3 24 | $226.5M | $377.2M | ||
| Q2 24 | $213.3M | $232.2M | ||
| Q1 24 | $71.0M | $376.5M |
| Q4 25 | $173.9M | $173.3M | ||
| Q3 25 | $219.5M | $351.6M | ||
| Q2 25 | $284.4M | $129.5M | ||
| Q1 25 | $72.8M | $386.3M | ||
| Q4 24 | $193.2M | $254.5M | ||
| Q3 24 | $224.7M | $300.7M | ||
| Q2 24 | $211.6M | $187.1M | ||
| Q1 24 | $67.0M | $338.3M |
| Q4 25 | 34.0% | 21.9% | ||
| Q3 25 | 42.6% | 44.0% | ||
| Q2 25 | 53.0% | 16.2% | ||
| Q1 25 | 14.6% | 48.6% | ||
| Q4 24 | 43.9% | 34.6% | ||
| Q3 24 | 49.5% | 40.2% | ||
| Q2 24 | 47.2% | 26.2% | ||
| Q1 24 | 15.4% | 49.9% |
| Q4 25 | 0.0% | 21.9% | ||
| Q3 25 | 0.8% | 26.3% | ||
| Q2 25 | 0.3% | 7.8% | ||
| Q1 25 | 0.4% | 9.4% | ||
| Q4 24 | 0.2% | 11.8% | ||
| Q3 24 | 0.4% | 10.2% | ||
| Q2 24 | 0.4% | 6.3% | ||
| Q1 24 | 0.9% | 5.6% |
| Q4 25 | 1.10× | 0.95× | ||
| Q3 25 | 1.44× | 1.66× | ||
| Q2 25 | 1.57× | 0.62× | ||
| Q1 25 | 0.46× | 1.43× | ||
| Q4 24 | 1.27× | 1.13× | ||
| Q3 24 | 1.67× | 1.22× | ||
| Q2 24 | 1.69× | 0.83× | ||
| Q1 24 | 0.55× | 1.23× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
FICO
| Business To Business Scores | $248.6M | 49% |
| Saa S Products | $115.7M | 23% |
| Platform Software | $73.9M | 14% |
| Business To Consumer Scores | $55.9M | 11% |
| Technology Service | $19.2M | 4% |
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
